ClinicalTrials.gg
CompletedNCT00890682Updated Aug 5, 2013Results posted

Study of Postoperative Analgesia in Bunionectomy

A Phase 3 interventional study of SKY0402 and Placebo in Bunion and Hallux Valgus, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-05.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
193
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Bunion with a site in United States — 1 open to participants now, 4 under way, 2 of them phase 3. Bunion · United States.

Enrollment
13th of 34
193 · median 124
Started
2009
the only one that year
Phase 3
12 of 37
1 open now
Registered
4th of 37
by date
Lead sponsor
4 of 37
Pacira Pharmaceuticals, Inc

Among the 37 studies in Bunion with a site in United States, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2009, is one of 12 in phase 3, and was the 4th registered.

Bunion

58 studies on the registry are indexed under Bunion; 5 are open to participants now.

Browse Bunion studies →

Open to participants now

1 of the 37 studies in Bunion with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1 Bunion study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Bunion with a site in United States, or all of them as a file.
02

Study summary

After undergoing bunion surgery, patients are given a pain medicine injection that may last for up to several days or a placebo. Their pain and pain medicine use is then monitored.

Read the detailed description

Following drug study administration, safety and efficacy assessments were conducted

03

Conditions studied

  • Bunion
  • Hallux Valgus

Keywords

  • Bunion
  • Bunionectomy
  • Osteotomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the Screening visit
  • Scheduled to undergo primary unilateral first metatarsal osteotomy without hammertoe
  • Female subjects must be surgically sterile or at least two years menopausal, or using an acceptable method of . If of , have a documented negative blood or urine pregnancy test within 24 hours before surgery
  • Clinical laboratory values less than or equal to twice the or, if abnormal, deemed not per the Investigator
  • Ability to provide , adhere to the study visit schedule and complete all study assessments

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant, nursing, or planning to become pregnant during the study or within one month after study drug administration
  • Chronic user of analgesic medications, including taking opioid medications for more than 14 days in the last 3 months, or non-opioid pain medications more than 5 times per week
  • Use of any non-steroidal anti-inflammatory drug (NSAID) including selective COX-2 inhibitor within three days of surgery
  • Use of acetaminophen within 24 hours of surgery
  • Use of selective serotonin reuptake inhibitors (SSRIs), gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) within three days of surgery
  • Current use of systemic glucocorticosteroids or use of systemic within one month of enrollment into this study
  • Peripheral neuropathy including diabetic neuropathy, chemotherapy-induced neuropathy, neuropathy
  • History of hepatitis
  • History of, suspected, or known addiction to or abuse of drugs or alcohol within the past two years
  • Failure to pass urine drug screen
  • Current evidence of alcohol abuse (greater than 4 units of alcohol per day: 1 unit = ½ pint of beer, 1 glass of wine or 1 oz. of spirits)
  • Evidence of peripheral ischemic disease
  • Type I or Type II diabetes
  • Current acute or chronic medical or major psychiatric disease that, in the opinion of the Investigator, would interfere with the evaluation of study drug efficacy or safety
  • in the last 2 years, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  • Administration of an drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study
  • Previous participation in a SKY0402 study
  • Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures
  • Current painful physical conditions or concurrent surgery other than bunionectomy that may require analgesic treatment (such as NSAID or opioid) in the postoperative period for pain that is not strictly related to the bunionectomy procedure and may confound the postoperative assessments
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
193 participants (actual)

Study arms

  • Experimental
    Sky0402

    Injection of Study Drug

    Drug: SKY0402

  • Placebo comparator
    Placebo

    Injection of study drug

    Drug: Placebo

Interventions

  • Local infiltration of 8cc SKY0402

    Also known as: EXPAREL

  • DrugPlacebo

    Local infiltration of 8cc Placebo

    Also known as: saline 0.9%

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores

    The AUC of the NRS-R pain intensity scores from time 0 through 24 hours The subject was to rest for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?"

    Time frame: 0-24 hours

Secondary outcomes

  1. Adverse Event Profile

    Participants with an Adverse Event through 72 hours or a Serious Adverse Event through 30 days

    Time frame: 30 days

07

Results

Posted Aug 5, 2013

Participant flow

Participant flow — Overall Study
MilestoneSKY0402Placebo
Started9796
Completed9394
Not completed42

Outcome measures

PrimaryArea Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores

The AUC of the NRS-R pain intensity scores from time 0 through 24 hours The subject was to rest for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?"

Time frame:
0-24 hours
Reported as:
Geometric mean · Units on a scale*hours
Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores
Units on a scale*hoursSKY0402Placebo
Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores124 ± 4.5146 ± 4.6
SecondaryAdverse Event Profile

Participants with an Adverse Event through 72 hours or a Serious Adverse Event through 30 days

Time frame:
30 days

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sky0402—0/97 (0%)56/97 (57.7%)
Placebo—1/96 (1%)63/96 (65.6%)
Most frequent serious events
Most frequent serious events
EventSky0402Placebo
Deep Vein ThrombosisVascular disorders0/971/96
Most frequent other events
Most frequent other events
EventSky0402Placebo
NauseaGastrointestinal disorders39/9736/96
VomitingGastrointestinal disorders27/9717/96
DizzinessNervous system disorders11/9725/96
HeadacheNervous system disorders5/978/96
PruritisSkin and subcutaneous tissue disorders5/976/96
SomnolenceNervous system disorders5/971/96

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sky0402PlaceboTotal
<=18 years000
Between 18 and 65 years9792189
>=65 years044
Age Continuous
Age Continuous(years)Sky0402PlaceboTotal
Mean42.4 ± 12.643.2 ± 13.342.8 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Sky0402PlaceboTotal
Female7584159
Male221234
Region of Enrollment
Region of Enrollment(participants)Sky0402PlaceboTotal
United States9796193
08

Study locations

1 site
  • Premier Research Group
    Austin, Texas 78705, United States
09

References and documents

Publications

  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
  • Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011 Sep;28(9):776-88. doi: 10.1007/s12325-011-0052-y. Epub 2011 Aug 12. PubMed 21842428 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 3 years 9 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2009
First posted
Apr 30, 2009
Start
Apr 2009
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results delay requested
Aug 25, 2010
Results first posted
Aug 5, 2013
Last update
Aug 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00890682
Responsible party
Sponsor
First posted
Apr 30, 2009
Start date
Apr 2009
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Aug 5, 2013
Last update
Aug 5, 2013

Study contacts

Stephen Daniels, DO
principal investigator · Premier Research Group Clinical Research Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion